Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 26,408

Document Document Title
WO/2019/129213A1
Disclosed are an amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines. The compound or the ph...  
WO/2019/128983A1
The present invention relates to a method for preparing an elagolix intermediate (formula IV); in the method, the intermediate is prepared by means of the following course, the method is simple and safe to operate, and yield is good, whi...  
WO/2019/133605A1
Provided herein is a novel process for the preparation of an amino-pyrimidine and salts thereof. Also provided herein are novel intermediates used in this process and their preparation.  
WO/2019/129310A1
Disclosed are a deuterated elagolix derivative, a pharmaceutical composition, and uses thereof. The structure of the deuterated elagolix derivative of the present invention is as shown in formula (X). The deuterated elagolix derivative a...  
WO/2019/120121A1
Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotope derivatives th...  
WO/2019/121352A1
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of pyrimidine compounds ...  
WO/2019/125798A1
The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating c...  
WO/2019/121544A1
The invention relates to substituted thiophenyl uracils of general formula (I) or the salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for...  
WO/2019/121543A1
The invention relates to substituted thiophenyl uracils of general formula (I) or salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for con...  
WO/2019/119486A1
Provided is a kinase inhibitor, comprising a compound of formula I, or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite, or a prodrug thereof. Further provided are a pharmaceutical composition comprising the...  
WO/2019/126443A1
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.  
WO/2019/122932A1
Compounds of general formula (I): (Formula (I)) wherein R1, R2, X1 and X2 are as defined herein are useful for the treatment of cancer, particularly solid tumours.  
WO/2019/126646A1
Described herein are genetic recognition reagents comprising terminal aromatic moieties that bind specifically to a template nucleic acid and concatenate. Also provided are methods of using the genetic recognition reagents, e.g., to trea...  
WO/2019/121408A1
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are de- fined according to the description, use of pyrimidine compound...  
WO/2019/120263A1
The present invention relates to an organic mixture and an application thereof in organic electronic devices. The organic mixture comprises a spirofluorene organic compound containing a fused heterocyclic ring and an aromatic fused heter...  
WO/2019/122151A1
The present invention relates a compound of formula (I) in Z-isomer form (Z-(l)) or a compound of formula (I) in E-isomer form (E-(l)) wherein: R2 is a radical of formula (II) and of formula (III); X1, X2, X3, X4 and X5 are CR3 and N; Y1...  
WO/2019/121547A1
The invention relates to substituted thiophenyl uracils of general formula (I) or the salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for con...  
WO/2019/117148A1
The purpose of the present invention is to provide a novel low molecular-weight compound having orexin receptor agonist activity that is expected to be useful for the prevention or treatment of narcolepsy, etc. The present invention prov...  
WO/2019/115019A1
The application relates to a process for the preparation of compound of formula (1) or a salt thereof (i.e. elagolix): The application also relates to solid crystalline forms of intermediates used in the process.  
WO/2019/112968A1
The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.  
WO/2019/111225A1
Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein....  
WO/2019/113071A1
Heterobifunctional small molecules including anaplastic lymphoma kinase (ALK) ligand conjugated to a degradation/disruption tag through a linker, which selectively degrade/disrupt ALK, ALK fusion proteins, and/or ALK mutant proteins, and...  
WO/2018/071315A3
In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1,Q, and R5 are as defined herein. The novel compou...  
WO/2019/101551A1
The present invention relates to phenylethers of formula (I) or their agriculturally acceptable salts or derivatives, wherein the variables are defined according to the description, processes and intermediates for preparing the phenyleth...  
WO/2019/101647A1
The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I)5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for pr...  
WO/2019/101053A1
Disclosed are a new crystal form of a rosuvastatin calcium intermediate, [4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfona mido)-5-pyrimidyl]triphenylphosphonium bromide, and a preparation method therefor. The XRPD spectrum of...  
WO/2019/101039A1
Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tau...  
WO/2018/125961A8
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...  
WO/2019/096209A1
Provided are a chiral 1,3-diarylimidazolium salt carbene precursor (S), a synthesis method therefor, a metal salt compound, and an application thereof. The chiral 1,3-diarylimidazolium salt carbene precursor catalyzes a reaction between ...  
WO/2019/094641A1
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or amelior...  
WO/2019/070167A8
The present group of inventions relates to novel compounds having formula (I), and to the salts, solvates or stereoisomers thereof, as well as to a pharmaceutical composition, a method of inhibiting the biological activity of epidermal g...  
WO/2019/090558A1
Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, b...  
WO/2019/090158A1
The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject ar...  
WO/2019/090081A1
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.  
WO/2019/089902A1
The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma1 receptor. The present application...  
WO/2019/087214A1
The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compo...  
WO/2019/085916A1
A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.  
WO/2019/079599A1
An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.  
WO/2019/076343A1
Disclosed are a PD-1/PD-L1 small-molecule inhibitor and a preparation method therefor and use thereof. In particular, disclosed are a compound which has a structure as shown in formula L, a stereoisomer or a tautomer thereof, or a pharma...  
WO/2019/076329A1
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N-H, O, S, or absent; (II) is a single bond or a double bond; each of X,...  
WO/2019/076904A1
The application relates to compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activi...  
WO/2019/079540A1
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering ...  
WO/2019/078246A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...  
WO/2019/072785A1
The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufac...  
WO/2019/071351A1
A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders. The compounds of Formula I display excellent brain penetration and an improved ...  
WO/2019/068726A1
The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfon...  
WO/2019/070169A1
The invention relates to a water-soluble liophilised form of (bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)- (4-nitrophenyl)methane) which has hepatoprotective activity and is designed to be used in medicine for the treatmen...  
WO/2019/070709A1
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/070167A1
The present group of inventions relates to novel compounds having formula (I), and to the salts, solvates or stereoisomers thereof, as well as to a pharmaceutical composition, a method of inhibiting the biological activity of epidermal g...  
WO/2019/066340A1
The present invention relates to an organic compound represented by formula 1, an organic optoelectronic device comprising the same, and a display device.  

Matches 301 - 350 out of 26,408